Skip to search formSkip to main content

TAK-491

Known as: TAK 491, TAK491 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Azilsartan medoxomil potassium salt (TAK-491) is an orally administered angiotensin II type 1 receptor blocker for the treatment… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
The absorption process in animals of TAK-491, designed as ester-based prodrug with medoxomil moiety, was evaluated. In the plasma… Expand
Is this relevant?
2011
2011
Increased expression of plasminogen activator inhibitor type-I (PAI-1) in vessel walls seems to accelerate atherosclerosis… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Review
2011
Review
2011
Objective: To evaluate the efficacy, safety, and clinical role of azilsartan medoxomil, an angiotensin II receptor blocker (ARB… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Review
2011
Review
2011
BACKGROUND Azilsartan medoxomil is an angiotensin receptor blocker, approved on February 25, 2011 by the US Food and Drug… Expand
Is this relevant?
2010
2010
PurposeWe assessed the effects of TAK-491 (a newly designed potent and selective ARB) alone and in combination with pioglitazone… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?